Category Archives: ClinCalc News

Introducing the PREVENT ASCVD Risk Calculator on ClinCalc.com

PREVENT 10-Year ASCVD Risk Calculator

ClinCalc.com is excited to announce the launch of the PREVENT ASCVD Risk Calculator, a validated online tool that estimates a patient’s 10-year risk of a first atherosclerotic cardiovascular disease (ASCVD) event or heart failure hospitalization using the 2023 PREVENT equations.

ASCVD risk estimation plays a central role in preventive cardiology and is used to guide decisions around statin therapy, antihypertensives, and other interventions. For the past decade, the 2013 Pooled Cohort Equations (PCE) have been the standard tool for cardiovascular risk assessment. However, with the release of the 2025 hypertension guidelines, the PREVENT equations are now the recommended method for risk estimation. PREVENT offers improved predictive accuracy, eliminates the use of race-specific equations, and incorporates additional clinical and social risk factors.

Why use the ClinCalc PREVENT calculator?

Continue reading →

ClinCalc DrugStats: Most Commonly Prescribed Medications in 2023

ClinCalc DrugStats 2023

ClinCalc has released the latest edition of the DrugStats database, featuring “The Top 200 Drugs of 2023.” DrugStats offers complimentary access to estimated prescription drug utilization data for the United States. With this data set, users can discern patterns in prescribing habits and access an evidence-based, reputable “top 200 drugs” (or “top 300 drugs”) list based on data provided by the US Government.

Where does the DrugStats data come from?

All medication utilization data comes from the annual Medical Expenditure Panel Survey (MEPS), a survey conducted by the Agency for Healthcare Research and Quality (AHRQ). This data is publicly available on the MEPS website. To implement MEPS into the ClinCalc DrugStats database, basic data sanitization and standardization are applied to maintain an accurate and reliable data set. Read more about the methodology on the DrugStats About page.

Continue reading →

Introducing RxFlip: The Ultimate App for Learning the Top 250 Drugs

RxFlip - Top 250 Drugs Adaptive Learning Flashcards and Quizzes

We’re excited to announce the launch of RxFlip — a new, adaptive-learning flashcard and quiz mobile app designed to help healthcare students and professionals master the top 250 drugs. Learn more about the app at RxFlip – Top 250 Drugs.

Built on a modern platform with a sleek design, RxFlip delivers high-yield drug information through adaptive-learning flashcards and dynamically generated quizzes. The app is perfect for healthcare providers or students wanting to review commonly prescribed medications or those preparing for board exams (e.g. NAPLEX, BCPS, PTCB, PANCE, or NCLEX).

Continue reading →

ClinCalc DrugStats 2021 Update – The Most Commonly Prescribed Drugs in the United States

ClinCalc has released this year’s update to the DrugStats database — “The Top 200 Drugs of 2019”. DrugStats provides free access to prescription drug utilization data estimates for the United States.  Using this data set, users can identify trends in prescribing practice and an official, reputable “top 200 drugs” list based on data provided by the U.S. Government.

Where does the DrugStats data come from?

All medication utilization data comes from the annual Medical Expenditure Panel Survey (MEPS), a survey conducted by the Agency for Healthcare Research and Quality (AHRQ) via the United States government. This data is publicly available on the MEPS website for free.  In order for the ClinCalc DrugStats database to implement the MEPS data, basic data sanitization and standardization measures are necessary to maintain an accurate and reliable data set.  Read more about the data set by clicking here. Continue reading →

RxHero for iOS: Educational Gaming of the Top 250 Drugs

Gamification - Motivate your studying by earning game points, ranks, and awards as you complete RxHero campaigns

ClinCalc is proud to announce a new iOS app — RxHero, an educational game for healthcare students and professional to learn the Top 250 Drugs.

Key Features of RxHero

  • Leverages simple gamification concepts (quest campaigns, in-game points, ranks) to motivate learners to continue to engage in studying
  • Uses the evidence-based ClinCalc DrugStats drug list top 250 drugs, which represents about 95% of all prescribed medications on the U.S. market
  • Adaptive, multi-modal learning to focus your attention on drug facts that are unlearned or difficult by presenting these drug facts in a variety of different ways (quiz questions, matching, and drug spelling)
  • Drug pronunciation is deeply integrated into the app so that you can hear the pronunciation of brand and generic names at any time while learning drug facts

Continue reading →

Add Brand/Generic Drug Names to Microsoft Office Word with the ClinCalc DrugSpell Dictionary File

By default, Microsoft Word and other Office products do not contain brand and generic medication names within the spelling dictionary.  For healthcare providers who conduct medical writing, publications, or PowerPoint lectures, this can lead to embarrassing spelling errors that are not captured by the spell check.

Spell checking drug names like atorvastatin (Lipitor®) can be frustrating. Avoid spelling errors (and the dreaded red squiggly lines) with the ClinCalc DrugSpell dictionary file. It’s free!

Introducing the ClinCalc DrugSpell Dictionary File

Continue reading →

The Top 200 Drugs of 2018

Top 200 Drugs of 2019 - The ClinCalc DrugStats Database

We’re proud to announce the annual update of the DrugStats database.  DrugStats provides free access to prescription drug utilization data estimates for the United States.  Using this data set, users can identify trends in prescribing practice and an official, reputable “top 200 drugs” list based on data provided by the U.S. Government.

Where does the DrugStats data come from?

All medication utilization data comes from the annual Medical Expenditure Panel Survey (MEPS), a survey conducted by the Agency for Healthcare Research and Quality (AHRQ) via the United States government. This data is publicly available on the MEPS website for free.  In order for the ClinCalc DrugStats database to implement the MEPS data, basic data sanitization and standardization measures are necessary to maintain an accurate and reliable data set.  Read more about the data set by clicking here.
 Continue reading →

Introducing the ClinCalc DrugStats Database and the 2017 Top 200 Drugs

ClinCalc DrugStats Database

We’re excited to announce the launch of our newest product at ClinCalc.com — the DrugStats Database!  This database provides free, web-based access to outpatient prescription utilization statistics for the United States encompassing more than 3 billion prescriptions annually.

Features of the ClinCalc DrugStats Database

By leveraging the database, users can identify trends and compare usage of approximately 500 different outpatient medications.  A few examples include: Continue reading →

Calculate a “Fragility Index” to see which clinical trials BARELY meet statistical significance

ClinCalc.com's Fragility Index Calculator

When evaluating a clinical trial, readers often jump to the P value of the primary endpoint to determine whether the results of a trial are “statistically significant” or not. Although the P value is truly a continuous variable, the scientific community has been conditioned to disregard all results with P values ≥ 0.05, but to fully endorse any trials with a “statistically significant” P value less than 0.05.

Putting the debate and controversy about P values aside for the moment, as a reader, would you be less impressed with a study that changed from being statistically significant to insignificant if one single patient changed from not having the primary endpoint to having the primary endpoint? Especially in an era with a blind reliance on P values, the knowledge of the “fragility” or “robustness” of a study’s P value is another useful data point for readers to critically understand and analyze the results of a clinical trial.

The Concept of the “Fragility Index” for Clinical Trials

Continue reading →